Establishing a surveillance programme for measurement of Neuraminidase Inhibitor susceptibility Maria Zambon Oct 2006 G224.

Slides:



Advertisements
Similar presentations
Evoluzione genetica di HIV ed evoluzione clinica della malattia AIDS: due aspetti correlati? Carlo Federico Perno.
Advertisements

Office of Infectious Diseases Computational Challenges for Infectious Diseases Michael Shaw, PhD OID/Office of the Director.
The pandemic and a brief ABC of influenza Thomas Abraham JMSC 6090.
The Antiviral Activity of Oseltamivir against H5N1 Human A/Vietnam/1203/04 and A/Turkey/15/06 Influenza Viruses in Ferrets Elena Govorkova, N.A. Ilyushina,
Zanamivir in the Management of Influenza A and B.
John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group Four: Antivirals and Non-Specific.
6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.
WHO Draft Rapid Response + Containment, May 2006.
WHO Draft Rapid Response + Containment, May 2006.
Influenza Sara Finestone April 8, The influenza virus causes 3-5 million cases of severe illness and up to 500,000 deaths annually.
Seasonal Influenza and Swine-Origin Influenza A (H1N1) Virus
Influenza Ieuan Davies. Signs and Symptoms Influenza is an acute, viral respiratory infection. Fever, chills, headache, aches and pains throughout the.
Avian Influenza - Pandemic Threat ? Reinhard Bornemann.
Influenza A Virus Pandemic Prediction and Simulation Through the Modeling of Reassortment Matthew Ingham Integrated Sciences Program University of British.
Virus Evolution Molecular Epidemiology of Viral Infections Jen-Ren Wang, Ph. D. 王貞仁 Dept. of Medical Laboratory Science and Biotechnology National Cheng.
NI Assays: Troubleshooting & Analysis of Curve Fitting Graph 1: Standard clinical isolate Good NA activity S shaped curve (observed points) IC50 in expected.
Influenza Neuraminidase Inhibitor IC 50 Data: Calculation, Interpretation and Statistical Analyses.
The Unique Resistance Profile of Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.
NS 2 Lipid Bilayer NA (Neuraminidase) HA (Hemagglutinin) M 2 (Ion channel) M 1 (Matrix protein) NP (Nucleocapsid) PB1, PB2, PA (Transcriptase complex)
ANTIVIRALS and IMMUNOTHERAPIES in PANDEMIC INFLUENZA IOM Briefing April 4, 2005 Frederick G. Hayden, M.D. Division of Infectious Diseases and International.
A PANDEMIC FLU SWINE FLU.
DR MOHAMMED ARIF. ASSOCIATE PROFESSOR. CONSULTANT VIROLOGIST. HEAD OF THE VIROLOGY UNIT. Viral infection of the respiratory tract -- 2.
EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global epidemics Influenza viruses.
EPIDEMIOLOGY AND PREVENTION OF INFLUENZA. Introduction Unique epidemiology: – Seasonal attack rates of 10% to 30% – Global pandemics Influenza viruses.
SPRINT-2/RESPOND-2 Boceprevir Plus Standard of Care Phase 3 Clinical Trials Analysis of Resistance Associated Variants by HCV Genotype 1 subtypes 1a and.
What should be taken into consideration when establishing antiviral resistance surveillance? Aeron Hurt WHO Collaborating Centre for Reference and Research.
Treatment of Influenza in Adults Andrew T. Pavia M.D. George and Esther Gross Professor and Chief Pediatric Infectious Diseases University of Utah.
Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,
سورة البقرة ( ۳۲ ). Influenza is a serious respiratory illness which can be debilitating and causes complications that lead to hospitalization and.
Antivirals for Pandemic Influenza Frederick G. Hayden, MD Division of Infectious Diseases and International Health University of Virginia School of Medicine.
Update of Antiviral Resistance in Seasonal and Pandemic Influenza Viruses 3 rd NIC Meeting, Beijing, China August th 2009 Aeron Hurt WHO Collaborating.
Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.
Lessons from the European Experience with A(H1N1) 2009 Angus Nicoll CBE European Centre for Disease Prevention and Control 3 rd meeting of the National.
1 Novel HIV Suppressive Approaches with Integrase Inhibitors Mark A Wainberg McGill University AIDS Centre Montreal, Canada.
Sheila Negrini Parmezan São Paulo, Introduction The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are currently the antiviral drugs.
Influenza A/H1N1 W. Rose H1N1 is a subtype of influenza type A Influenza types B and C also exist but less common, less infectious, and drift.
Influenza Today Joseph Mester, Ph.D. September 24, 2009.
1 Resistance and Tropism - Maraviroc Lisa K. Naeger, Ph.D. Division of Antiviral Products Food and Drug Administration April 24, 2007 FDA Antiviral Advisory.
X. James Li, Ph.D. Cellex, Inc.. Topics  Homogeneous Biochemiluminescence Assays (HBA) and Its Use for Detection of Influenza Viral Neuraminidase (NA)
The Flu Pandemic of 1918 The “Spanish flu” pandemic that swept around the world from June 1918 to December 1919 killed between 50 and 100 million people.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group One: Influenza Virulence and Antigenic.
Avian Influenza H5N1 Prepared by: Samia ALhabardi.
Interpretation of Raw Data: NA Activity and IC50 Assays Angie Lackenby.
How to avoid a resistance issue with the first generation protease inhibitors ? O. Lada PHD Service d’Hépatologie et INSERM CRB3, AP-HP Hopital Beaujon,
ANTIVIRAL AGENTS FOR THE PREVENTION AND TREATMENT ON INFLUENZA.
It’s Just Not the Flu Anymore Rick Hong, MD Associate Chairman CCHS EMC Medical Director, PHPS.
Copyright © 2007 Merck & Co., Inc., Whitehouse Station, New Jersey, USA All rights Reserved Resistance to the HIV-Integrase Inhibitor Raltegravir: Analysis.
Risk factors for severe disease from pandemic (H1N1) 2009 virus infection reported to date are considered similar to those risk factors identified for.
Phar. Nhat Mang/ Roche Vietnam
“Neutralizing Antibodies Derived from the B Cells of 1918 Influenza Pandemic Survivors” (Yu et. al) Daniel Greenberg.
NI Assays: Troubleshooting & Analysis of Point-to-Point IC50 determination Graph 1: Standard clinical isolate – Technical Error Dark blue = first test.
SWINE FLU. WHAT IS SWINE FLU? Swine Influenza (swine flu) is a respiratory disease of Type A influenza viruses that causes regular outbreaks in pigs.
Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.
Will it be just a scare … or a scar on human history? Bird flu.
OUR MODERN SOCIETY IS FUNDAMENTALLY DEPENDENT ON SCIENTIFIC RESEARCH AND DEVELOPMENT. YOUR FUTURE WILL DEPEND ON SOCIETAL DECISIONS IN THE GENERAL AREA.
Antivirals Essential idea
Antiviral Medications
Figure 2. Reaction strategy for the synthesis of 6SLN-lipo PGA
VIRAL INFLUENZA.
Antivirals Essential idea
Viral Genetics.
Antivirals Essential idea
What makes H5N1 Avian influenza “Avian”
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Volume 3, Issue 4, Pages (April 2013)
Impact of Baseline NNRTI Mutations on the Virologic Response to TMC125 in the Phase III Clinical Trials DUET-1 and DUET-2 J Vingerhoets, A Buelens, M.
Parallel evolution of influenza across multiple spatiotemporal scales
Avian influenza ( Bird flu )
Presentation transcript:

Establishing a surveillance programme for measurement of Neuraminidase Inhibitor susceptibility Maria Zambon Oct 2006 G224

Practicalities Source of isolates Viral subtype Assay type Which drug Which control viruses How to interpret data Phenotype vs Genotype Analysis of mixtures

Source of Isolates

Detection Of Antiviral Resistant Influenza During Treatment Frequency of resistance OseltamivirM2 inhibitor Out-patient adults Out-patient children 0.4% 5.5% ~30% Inpatient children 18% 80% Immunocompromised Surveillance Yes 0.1-1% >33% Roberts N. Phil Trans R Soc Lond 356:1895, 2001 Kiso et al. Lancet 364: 759, 2004

Resistance to Oseltamivir in Children Feb – Mar 2002, Jan – Feb 2003 (Japan) 50 children(median age 3-7), treated twice daily(4mg/kg/day) 33 positive for H3N2 after treatment NA resistance mutation in 9(18%) from 4 days p.t.; R292K(6), G119V(2), N294S(1). Mutant only(3); mutant+wt(6) 7yr (0/7) Low immunity comparable to pandemic situation ( Kiso et al. Lancet 364: 759, 2004)

YearA (H1N1)A (H1N2)A (H3N2)BTotal Resistant IC (12)1(0.2)373 (80)37 (8) 1/ (48)  100 (12)340 (40) 3/ (17)40 (2)409 (39)366 (37)4/980 All years622 (27)40 (2)882 (40)743 (32)7/2287 Global Surveillance No & (%) Monto et al, 2006

Conclusions Detection of resistant variants at very low level No evidence of increased frequency over time/shift susceptibilities Novel mutations Relationship between phenotype and genotype to be further defined Role of HA in altered NI susceptibility?

Viral Subtype

NA mutations, preclinical & clinical G224

Influenza Isolates Log (IC50)

H3N2 H1N1 B Fluor Chemi Log IC50 (nM) for Zanamivir and GS4071 by subtype R152K w1 H274Y w1 m1 R292K w1 w2 R152K w1 H274Y w1 E119V R292K w1 w2 L o g I C R152K w1 H274Y w1 m1 R292K w1 w2 R152K w1 H274Y w1 E119V R292K w1 w2 L o g I C Z G

Oseltamivir Resistance N2, Japan, Single season survey of NAI resistance –~ 6M treatment courses (or ~5% of population) –Outpatient isolates from 74 public health labs –Phenotypic susceptibility by NAI assay 3/1,180 (0.3%) of influenza A(H3N2) isolates resistant –2 E119V, 1 A292K Very low frequency of resistance in community isolates despite substantial oseltamivir use –Likely due to low-level transmission of resistant variants and not primary NA inhibitor resistance Neuraminidase Inhibitor Susceptibility Network. WHO Weekly Epi Record, April 29, 2005

Oseltamivir Resistance In N1 Neuraminidase Single nucleotide substitution (His274Tyr) → ↓oseltamivir susceptibility (≥ 400–fold) Frequency drug therapy of N1: – H1N1: children 16% (7/43), adults 4% (2/50) – H5N1: 2/8 (25%) Reduced replication in cell culture (> 2.0 log 10 ) – ↓infectivity in mouse (1,000-fold) and ferret (>10-fold) – Variable ↓ pathogenicity in ferret Transmissible in ferret model Ives et al. Antiviral Res 5:307, 2002 Herlocher et al. JID 190:1627, 2004

Oseltamivir Therapy in H5N1, Thailand and Vietnam, Oseltamivir treatment No. patientsNo. (%) survivors Yes256 (24%) No123 (25%) Writing Committee. NEJM 353:1374, 2005

Pharyngeal Viral Loads during Oseltamivir Treatment of H5N1 de Jong et al. NEJM 353:25, 2005

Oseltamivir Treatment Failure in H5N1 Late initiation - pulmonary injury Prolonged viral replication - primary infection,  replication competence, immune evasion Altered pathogenesis –Viral virulence factors –Extra-pulmonary dissemination –Pro-inflammatory host immune responses Inadequate dose regimen –Inadequate absorption (diarrhea, GI dysfunction) Antiviral resistance emergence

Summary Little evidence of existence of naturally resistant virus isolates The precise orientation and the immediate surrounding residues of conserved NA site differs between subtypes (? different enzymes) Drug binding will not be identical across all subtypes Resistance ‘strategy’ not identical between subtypes

Which drug

NA Inhibitor Resistance Profiles NA mutationNA type/ subtype Susceptibility in the NAI assay (fold  ) OseltZanaPeramA E119VA/N2R (>50)S (1) R292KA/N2R (>1000)S (4-25)R (40-80)S (8) H274YA/N1R (>700)S (1)R (40-100)S (3) R152KBR (>30-750)R (10-100)R (>400)R (150) Mishin et al. AAC 49:4516, 2005; Wetherall et al. AAC 41:742, 2003

Assay Methodology

Possible methods Cell culture based Enzyme Genotype

NI Susceptibility Screening Methodology Based on methodology developed by Potier et al (1979) Fluorometric: measures level of 4-methyumbelliferone cleaved by influenza NA from the fluorogenic substrate 2’-(4-methyumbelliferyl)- α-D-N-acetylneuraminic acid (MUNANA) (Sigma-Aldrich) Viruses are pre-titrated to ensure equivalent NA activities are compared against inhibitors IC50 values (concentration of inhibitor required to reduce NA activity by 50%) are calculated using curve fitting software Chemi-luminescent substrate available (Applied Biosystems) and methodology is under development

Comparison of Assay Methodology CLF1 Virus TitrationNoYes [Inhib]0.03 – 1000nm0.01 – 5000nm SubstrateNA – starMUN [Substrate]100µm µm Substralet ½MinsHours Assay duration60mins1-2 hours Isolate volume~300µl µl Instrument Cost Luminometer £20 Fluorimeter £10

Neuraminidase Inhibitor Susceptibility Screening 292R: 0.6nM 292K: 15.9nM 119E: 0.95nM 119V: 1.47nM 292R: 0.59nM 292K: >4000nM 119E: 0.74nM 119V: 66.63nM Weatherall et al,

Availability of reagents for laboratories setting up NI assays Substrates Fluorescent assay MUNANA commercially available Chemiluminescent (CL) assay – NA-star now available in kit form Inhibitors Zanamivir – Relenza TM contains the active ingredient + lactose Oseltamivir carboxylate – Tamiflu TM contains the prodrug oseltamivir phosphate, cannot be used in assays as needs activation to oseltamivir carboxylate. Need MTA from Roche. Equipment Any fluorimeter can be used for MUNANA, substrate stable for hours Any luminometer can be used, but reaction half life 5 mins. For multiple samples need automatic addition of enhancer.  NISN selected the chemiluminescent assay due to its higher sensitivity,  Fluorescent assay is the most practical for regional laboratories  Kit format CL assay offers new possibilities for regional laboratories

H3N2 H1N1 B Fluor Chemi Log IC50 (nM) for Zanamivir and GS4071 by subtype R152K w1 H274Y w1 m1 R292K w1 w2 R152K w1 H274Y w1 E119V R292K w1 w2 L o g I C R152K w1 H274Y w1 m1 R292K w1 w2 R152K w1 H274Y w1 E119V R292K w1 w2 L o g I C Z G

How to interpret data

Reference Panel SubtypeVirusMutation CK Titre (pfu/ml) Oseltamivir IC50(nM) Fold Change Zanamivir IC50(nM) Fold Change H3N2 A/Texas/36/91 WT (292R) 1.6x K 3.3x A/Sydney/5/97 WT (119E) 8.5x V 3.5x H1N1 A/Wuhan/359/95 WT (274H) 1.5x Y 1.3x BB/Memphis/20/96 WT (152R) 2.1x K 1.1x

European Strain IC50 Data: Season

Routine Surveillance of UK and European Isolates 2004/5 season Influenza B H3N2 H1N1 Oseltamivir Zanamivir

Identification and Analysis of Mixed Strains Depends heavily on criteria determining normal range 1.6SD above median= top 5% (red line) 3SD above median= unusually high IC50 (black line) OR: calculate 95th percentile after removing major outliers H3N2 + Oseltamivir

NI Testing Algorithm NI phenotypic assay in duplicate Repeat NI testing x2 in duplicate Entry of results into central database Genotypic analysis e.g. Sequencing Cloning & sequencing Other methods for mixture analysis IC50/curve in ‘Normal Range’ for season and subtype IC50 >1.6SD above median season and subtype Mean IC50 in ‘Normal Range’ for season and subtype Mean IC50 >1.6SD above median season and subtype Sequencing of a percentage of ‘normal range’ isolates for baseline

Naturally occurring altered susceptibility isolates There may be altered susceptibility due to normal drift mutations These mutations are different to those observed after drug treatment, and are not necessarily in conserved residues Although there is high conservation of residues in and around the active site, there are clearly also secondary structural effects outside the active site which can affect drug binding Structural data is needed to understand how these background residues affect the active site

Genotype:phenotype relationship >20 fold mean IC50 subtype Known resistance mutations 274, 198 ? New resistant variants Y155H fold > mean IC50 subtype Altered susceptibility viruses E41G, Q226H, I222T No known mutations

Analysis of Mixtures

292 K

B 152

B/Perth/211/2001  Not from drug treated patient  Medium resistance to oseltamivir and BCX-1812, low resistance to zanamivir in CL assay  Resistance to all three inhibitors in Fluorescent assay  Initial sequencing by 2 independent laboratories did not detect any mutation  Subsequent sequencing of cloned NA and plaque purified virus mixed population, with D198 in sensitive and D198E mutation in resistant population

Practicalities for European/national surveillance Source of isolates Viral subtype Assay type Which drug Which control viruses How to interpret data Phenotype vs Genotype Analysis of mixtures